Journal article

Andrographolide stabilized-silver nanoparticles overcome ceftazidime-resistant Burkholderia pseudomallei: study of antimicrobial activity and mode of action

S Thammawithan, C Talodthaisong, O Srichaiyapol, R Patramanon, JA Hutchison, S Kulchat

Scientific Reports | NATURE PORTFOLIO | Published : 2022

Abstract

Burkholderia pseudomallei (B. pseudomallei) is a Gram-negative pathogen that causes melioidosis, a deadly but neglected tropical disease. B. pseudomallei is intrinsically resistant to a growing list of antibiotics, and alternative antimicrobial agents are being sought with urgency. In this study, we synthesize andrographolide-stabilized silver nanoparticles (andro-AgNPs, spherically shaped with 16 nm average diameter) that show excellent antimicrobial activity against B. pseudomallei, including ceftazidime-resistant strains, being 1–3 orders of magnitude more effective than ceftazidime and 1–2 orders of magnitude more effective than other green-synthesized AgNPs. The andro-AgNPs are meanwhil..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Department of Chemistry, University of York


Funding Acknowledgements

ST was supported by Materials Chemistry Research Center (MCRC), Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science (FoS), Khon Kaen University (KKU), Khon Kaen, Thailand. The instrument service in this work was supported by the Research Instrument Center (RIC), KKU and Central Equipment, FoS, KKU. ICP-OES was provided by the department of Chemistry, FoS, KKU. B. pseudomallei clinical strains were kind gifts from the Melioidosis Research Center (MRC), KKU. E. coli O157:H7 was obtained from Protein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), KKU. SK acknowledges financial and laboratory support from FoS, KKU and PERCH-CIC, Ministry of Higher Education, Science, Research and Innovation. JAH acknowledges support from an Australian Research Council (ARC) Future Fellowship (FT180100295).